Oncology and Hematology

Partnering to overcome the complex challenges in oncology studies throughout the lifecycle of your product.

Small and mid-sized companies need the right partner.

Oncology remains the therapeutic area with the lowest success rate in clinical trials, underscoring the need for innovative approaches and a partner with deep experience in this fast-evolving, complex field.

As a specialized clinical solutions company primarily focusing on small to mid-sized biotechs, Allucent excels at designing and executing oncology and hematology clinical trials. Our expertise encompasses all development phases (I-IV), solid tumors, and hemato-oncology indications. We provide guidance and insight in optimized clinical strategy, choice of endpoints based on the mode of action or tumor biomarkers, patient selection, feasibility studies, up-to-data trend analysis, and results reporting.

A patient-centric approach is assured by clinical development informed by the special needs of oncology patients and supported by state-of-the-art enabling technologies, ranging from digital patient engagement strategies and eConsent to sensor technology and implementation. We are working at the forefront of oncology projects with cutting-edge treatments. Our network of medical and research experts can assist you with the right advice and insights. Our regulatory perspective is crucial to planning for study design, choice of endpoints, data strategy, and so much more and is provided as a key element of our strategic guidance for early planning and continuing through post-approval.


Oncology trials require oncology experts.

Supporting drug development for cancer treatment requires multilayered proficiency: in the science, in the different aspects of clinical research, and in the ability to understand the emotional and physical experience of trial participants. Every phase of a clinical trial is different. Beginning with Early Phase through Phase II, III, and beyond, Allucent has deep expertise in many indications and therapeutic classes and is confident in taking on the full complexity inherent in cancer research. Our extensive experience with full-service clinical trials and consulting projects has provided us with ample hands-on knowledge of a wide variety of indications.



Solid Tumors 

  • All comer (all solid tumors)
  • Brain tumors (including GBM)
  • Bladder cancer
  • Breast cancer
  • Cervical cancer
  • Colorectal cancer
  • Endometrial cancer
  • Gastric cancer
  • Head and neck cancer
  • Liver cancer
  • Lung cancer (including NSCLC)
  • Melanoma
  • Neuroendocrine tumors
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Renal cancer
  • Sarcoma


  • All comer (all hemato-oncology)
  • Acute lymphoblastic leukemia (ALL)
  • Acute myeloid leukemia (AML)
  • Chronic lymphocytic leukemia (CLL)
  • Chronic myeloid leukemia (CML)
  • Lymphoma
  • Multiple myeloma
  • Myelofibrosis
  • Myelodysplastic syndromes
  • Graft versus host disease
  • Veno-occlusive disease



  • Anemia
  • Anticoagulant Reversal
  • Autoimmune Hemolytic Anemia
  • Blood Loss -
  • Essential Thrombocythaemia
  • Graft Versus Host Disease
  • Hereditary Angioedema
  • Hyperbilirubinemia (Genetic)
  • Neutropenia
  • Paroxysmal Nocturnal
  • Sickle Cell Anemia
  • Thrombotic Thrombocytopenic Purpura


  • Antibodies (e.g., monoclonal, bi-specific, antibody drug conjugates (ACDs), checkpoint inhibitors)
  • Peptides
  • Cell based
  • autologous & allogenic (e.g., dendritic cell (DC), natural killer (NK), T cell, stem cell)
  • Hormonal (e.g., hormone receptor inhibitors, liposomal corticosteroids)
  • Vaccines (e.g., bacterial vaccines, DNA vaccines, peptide vaccines, RNA vaccines, tumor-derived vaccines)
  • Oncolytic viruses
  • Radiolabeled compounds


  • Antisense oligonucleotides
  • miRNA compounds

Small Molecules 

  • Chemotherapy (e.g., alkylating agents, anthracyclines, antimetabolites, anti-microtubule agents, taxanes, topoisomerase inhibitors) 
  • Inhibitors (e.g., angiogenesis inhibitors, HDAC inhibitors, integrin receptor antagonists, PARP inhibitors, protein kinase inhibitors, tyrosine kinase inhibitors (TKIs)

A commitment to delivering therapies that can deliver cures.

The Allucent team has many years of experience in traditional therapies, as well as the promising new therapeutic classes including molecularly targeted agents, immunotherapies, and cell and gene therapies. We are also well-versed in different combination therapies. We have substantial experience in anticancer vaccines, antibodies (monoclonal, bispecific, and ADCs); nanoparticle formulations; metabolic regulators; and modified chemotherapies for enhanced efficacy.

Our experts have deep knowledge of the novel trial designs emerging in modern practice, specifically in oncology and rare diseases. We have an impressive track record with advanced therapy medicinal products (ATMPs), medicines for human use based on genes, tissues, or cells. Allucent has collaborated on more than 60 research projects involving cell and gene therapy products and similar biologics for oncology, as well as several other therapeutic areas.

Beyond our specialization in Early Phase trials, we have substantial experience in conducting Late Phase, pivotal, and post-marketing trials, as well as compassionate use/early access programs. From clinical study design to clinical trial management, medical writing, clinical data management, and more, Allucent is the ideal partner.

Explore More

Rare Diseases and Orphan Drugs

Learn More

Infectious Disease and Vaccine

Learn More

Cell and Gene Therapy

Learn More

Central Nervous System

Learn More

Autoimmune and Inflammation

Learn More

Allergy and Asthma

Learn More